drugset

Drugs / EOM613

Follow last change Mar 2022 re-read 3 minutes ago

EOM613

Oligonucleotide (other) targets IL6

Developed for: acute respiratory distress syndrome · COVID-19 · pneumonia
Investigated by: EOM Pharmaceuticals

Trials 1

today NCT05212532 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05212532	Aug 2021 → Feb 2022	COVID-19, acute respiratory distress syndrome, pneumonia	EOM Pharmaceuticals	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2020-12-24	EOM Pharmaceuticals	Regulatory EOM PHARMACEUTICALS ANNOUNCES ITS PRE-IND MEETING REQUEST WITH U.S. FDA TO EVALUATE PLANS FOR A PHASE 2 CLINICAL TRIAL OF ITS INVESTIGATIONAL DUAL-ACTING, BROAD-SPECTRUM IMMUNOMODULATOR IN COVID-19 PATIENTS eompharma.com ↗

All press releases naming this drug 2 releases

Date	Issuer	Release
2021-08-24	EOM Pharmaceuticals	EOM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN R1: RESCUE PHASE 1/2A OPEN-LABEL TRIAL EVALUATING EOM613 IN HOSPITALIZED COVID-19 PATIENTS WITH SEVERE SYMPTOMS IN BRAZIL eompharma.com ↗
2020-12-24	EOM Pharmaceuticals	EOM PHARMACEUTICALS ANNOUNCES ITS PRE-IND MEETING REQUEST WITH U.S. FDA TO EVALUATE PLANS FOR A PHASE 2 CLINICAL TRIAL OF ITS INVESTIGATIONAL DUAL-ACTING, BROAD-SPECTRUM IMMUNOMODULATOR IN COVID-19 PATIENTS eompharma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	EOM613	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05212532 ↗
Modality	Oligonucleotide (other)	“EOM613 is a peptide nucleic acid with novel immune-modulating properties” NCT05212532 ↗
Route	Subcutaneous	“EOM613 is to be administered subcutaneously (SC) at a dose of 2 mL once daily (QD) for 10 days” NCT05212532 ↗
Target	IL6	“including modulation of IL-6 expression” NCT05212532 ↗